708 patients received at least one Ra223 injection and 683 (548 symptomatic, 135 asymptomatic) received enough treatment to be evaluated. Asymptomatic patients received fewer prior treatments of abiraterone (25% vs 35%), enzalutamide (4% vs 8%), and docetaxel (52% vs 62%). Asmptomatic patients were more likely to complete the full treatment of 6 cycles of Ra223 (71% vs 55%). In addition, adverse events were less common in asymptomatic patients.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Presented By: Joe M. O’Sullivan from The Center for Cancer Research and Cell Biology, Queen’s University, Belfast, and the Northern Ireland Cancer Center, Belfast, Northern Ireland
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.